Puma Biotechnology, Pierre Fabre enter into Exclusive License Agreement
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire
Puma Biotechnology | Evaluate
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Bio: Sifting Through The Q4 Earnings Report (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotech Expands Pierre Fabre License to Add Countries
Accord entre Pierre Fabre et Puma Biotechnology
Pierre Fabre and ValenzaBio collaborate on anti-IGF-1R antibody for TE
Blue March: Pierre Fabre supports colorectal cancer awareness month
Fight against cancer : our therapeutic responses | Pierre Fabre
Disappointing Nerlynx sales shows Pierre Fabre timing is everything | Evaluate
Fight against cancer : our therapeutic responses | Pierre Fabre
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Puma regains China rights to Nerlynx and amends deal with Fabre
Pierre Fabre engagements | NERLYNX
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
Puma Bio: A Contrarian Investment That Requires Patience (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
Pierre Fabre étend ses droits sur le Nerlynx de Puma Biotechnology
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Puma and CANBridge cancel licensing deal for $20m
Puma regains China rights to Nerlynx and amends deal with Fabre
Partners of the Pierre Fabre Group: from health to beauty
